Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
DSM-Firmenich, (Formerly: Glycom A/S), Hørsholm, Denmark.
EBioMedicine. 2024 Jun;104:105182. doi: 10.1016/j.ebiom.2024.105182. Epub 2024 Jun 4.
Human milk oligosaccharides (HMOs), their determinants, infant gut microbiota and health are under extensive research; however, seldom jointly addressed. Leveraging data from the HELMi birth cohort, we investigated them collectively, considering maternal and infant secretor status.
HMO composition in breastmilk collected 3 months postpartum (n = 350 mothers) was profiled using high-performance liquid chromatography. Infant gut microbiota taxonomic and functional development was studied at 3, 6, and 12 months (n = 823 stool samples) via shotgun metagenomic sequencing, focusing on HMO metabolism via glycoside hydrolase (GH) analysis. Maternal and infant secretor statuses were identified through phenotyping and genotyping, respectively. Child health, emphasizing allergies and antibiotics as proxies for infectious diseases, was recorded until 2 years.
Mother's parity, irritable bowel syndrome, gestational diabetes, and season of milk collection associated with HMO composition. Neither maternal nor infant secretor status associated with infant gut microbiota, except for a few taxa linked to individual HMOs. Analysis stratified for birth mode revealed distinct patterns between the infant gut microbiota and HMOs. Child health parameters were not associated to infant or maternal secretor status.
This comprehensive exploration unveils intricate links between secretor genotype, maternal factors, HMO composition, infant microbiota, and child health. Understanding these nuanced relationships is paramount for refining strategies to optimize early life nutrition and its enduring impact on long-term health.
Sweet Crosstalk EU H2020 MSCA ITN, Academy of Finland, Mary and Georg C. Ehrnrooth Foundation, Päivikki and Sakari Sohlberg Foundation, and Tekes.
人乳寡糖（HMOs）、其决定因素、婴儿肠道微生物群和健康是广泛研究的对象；然而，很少将它们联合起来进行研究。利用 HELMi 出生队列的数据，我们考虑到母婴分泌状态，联合研究了这些因素。
在产后 3 个月收集的母乳中，使用高效液相色谱法对 HMO 组成进行分析。通过宏基因组测序研究婴儿肠道微生物群的分类和功能发育，重点分析 HMO 代谢的糖苷水解酶（GH）分析，在 3、6 和 12 个月（n=823 个粪便样本）进行。通过表型和基因型分别鉴定母婴分泌状态。记录儿童健康状况，重点关注过敏和抗生素作为传染病的替代指标，直至 2 岁。
母亲的产次、肠易激综合征、妊娠糖尿病和哺乳期季节与 HMO 组成有关。母婴分泌状态与婴儿肠道微生物群无关，除了少数与个别 HMO 相关的分类群。按分娩方式分层的分析揭示了婴儿肠道微生物群和 HMO 之间存在不同的模式。儿童健康参数与婴儿或母婴分泌状态无关。
这项全面的探索揭示了分泌基因型、母婴因素、HMO 组成、婴儿微生物群和儿童健康之间错综复杂的联系。了解这些细微的关系对于完善优化早期生命营养及其对长期健康的持久影响的策略至关重要。
Sweet Crosstalk EU H2020 MSCA ITN、芬兰科学院、玛丽和乔治·克恩鲁特基金会、Päivikki 和 Sakari Sohlberg 基金会以及 Tekes。
